Last updated on April 2019

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer


Brief description of study

A national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in women and men with HR+, HER2-negative advanced or metastatic breast cancer

Clinical Study Identifier: NCT03096847

Contact Investigators or Research Sites near you

Start Over

Novartis Investigative Site

Muenchen, Germany

Novartis Investigative Site

Recklinghausen, Germany

Novartis Investigative Site

Luebeck, Germany

Novartis Investigative Site

Aachen, Germany

Novartis Investigative Site

Augsburg, Germany

Novartis Investigative Site

Berlin, Germany

Novartis Investigative Site

Bielefeld, Germany

Novartis Investigative Site

Boeblingen, Germany

Novartis Investigative Site

Bottrop, Germany

Novartis Investigative Site

Chemnitz, Germany

Novartis Investigative Site

Dessau-Rosslau, Germany

Novartis Investigative Site

Donauwoerth, Germany

Novartis Investigative Site

Dresden, Germany

Novartis Investigative Site

Duesseldorf, Germany

Novartis Investigative Site

Erlangen, Germany

Novartis Investigative Site

Esslingen, Germany

Novartis Investigative Site

Frankfurt, Germany

Novartis Investigative Site

Freiburg, Germany

Novartis Investigative Site

Fuerstenwalde, Germany

Novartis Investigative Site

Fuerth, Germany

Novartis Investigative Site

Goettingen, Germany

Novartis Investigative Site

Goslar, Germany

Novartis Investigative Site

Greifswald, Germany

Novartis Investigative Site

Halle Saale, Germany

Novartis Investigative Site

Hamburg, Germany

Novartis Investigative Site

Hannover, Germany

Novartis Investigative Site

Heidelberg, Germany

Novartis Investigative Site

Hildesheim, Germany

Novartis Investigative Site

Homburg, Germany

Novartis Investigative Site

Karlsruhe, Germany

Novartis Investigative Site

Koblenz, Germany

Novartis Investigative Site

Kulmbach, Germany

Novartis Investigative Site

Landshut, Germany

Novartis Investigative Site

Langen, Germany

Novartis Investigative Site

Leipzig, Germany

Novartis Investigative Site

Loerrach, Germany

Novartis Investigative Site

Mannheim, Germany

Novartis Investigative Site

Marburg, Germany

Novartis Investigative Site

Minden, Germany

Novartis Investigative Site

Moenchengladbach, Germany

Novartis Investigative Site

Muehlhausen, Germany

Novartis Investigative Site

Muenster, Germany

Novartis Investigative Site

Neuruppin, Germany

Novartis Investigative Site

Nuernberg, Germany

Novartis Investigative Site

Offenbach, Germany

Novartis Investigative Site

Oldenburg, Germany

Novartis Investigative Site

Passau, Germany

Novartis Investigative Site

Potsdam, Germany

Novartis Investigative Site

Ravensburg, Germany

Novartis Investigative Site

Rotenburg, Germany

Novartis Investigative Site

Saarbruecken, Germany

Novartis Investigative Site

Schweinfurt, Germany

Novartis Investigative Site

Stuttgart, Germany

Novartis Investigative Site

Torgau, Germany

Novartis Investigative Site

Troisdorf, Germany

Novartis Investigative Site

Tuebingen, Germany

Novartis Investigative Site

Velbert, Germany

Novartis Investigative Site

Voelklingen, Germany

Novartis Investigative Site

Weinheim, Germany

Novartis Investigative Site

Wetzlar, Germany

Novartis Investigative Site

Wiesbaden, Germany

Novartis Investigative Site

Wuerzburg, Germany

Novartis Investigative Site

Wurzburg, Germany

Novartis Investigative Site

Georgsmarienhütte, Germany

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.